You are here: Industry Insights > AGVHD

News List

First drug for acute graft-versus-host disease prevention approved by FDA EuropeanPharmaceuticalReview
December 23, 2021
BMS’s Orencia (abatacept) has been approved by the US FDA for prophylaxis of acute graft-versus-host disease (aGvHD) in patients aged two years plus.
FDA Approves First Drug to Prevent Graft Versus Host Disease FDA
December 16, 2021
Today, the U.S. Food and Drug Administration approved Orencia (abatacept) for the prophylaxis (prevention) of acute graft versus host disease (aGVHD), a condition that occurs when donor bone marrow or stem cells attack the graft recipient...
Microbiome biotherapeutic shows promise in acute graft-versus-host disease europeanpharmaceuticalreview
March 22, 2021
MaaT013 was safe and generated complete or very good partial responses in a third of patients with steroid-refractory, gastrointestinal-predominant acute graft-versus-host disease.
Mallinckrodt Announces Interim Analysis Results for Therakos Platform Trial americanpharmaceuticalreview
February 22, 2019
Mallinckrodt announced interim analysis results of its company-sponsored, Phase 3, single-arm, open-label, multi-center study assessing the efficacy of treating steroid-refractory ....
Mesoblast's Trial Data In AGVHD: An IOMachine Runthrough seekingalpha
September 04, 2018
When I think of Mesoblast (MESO), the negatives I have are: one, this company is based outside US so there’s that much less scrutiny, two, the hyperbole surrounding stem cells, as a Seeking Alpha contributor put it two years ago, and three, these serial a